Pacific Edge (ASX:PEB, NZE:PEB) noted that the "Genetic Testing in Oncology: Specific Tests" local coverage determination became effective on April 24 in the US, halting Medicare coverage of its Cxbladder tests, according to Monday's Australian and New Zealand bourse filings.

A Pennsylvania District Court Judge ruled that her court lacks the jurisdiction to hear the firm's claim against Medicare administrative contractor Novitas and the US Centers for Medicare and Medicaid Services.

Its advocacy efforts also did not yield a change to the effective date or retirement of the local coverage determination.

Pacific Edge currently generates around 60% of its US revenue from Medicare. It will not seek re-coverage of Cxbladder Detect as no new evidence has been published that can be submitted for reconsideration. Detect users will be required to move over to the Triage test.